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 Abstract 
Objectives 
Exposure-based cognitive behavioural therapy (eCBT) is an effective treatment for anxiety 
disorders. Response varies between individuals. Gene expression integrates genetic and 
environmental influences. We analysed the effect of gene expression and genetic markers 
separately and together on treatment response. 
Methods 
Adult participants (n≤181) diagnosed with panic disorder or a specific phobia underwent eCBT 
as part of standard care. Percentage decrease in the Clinical Global Impression severity rating 
was assessed across treatment, and between baseline and a six month follow-up. 
Associations with treatment response were assessed using expression data from 3,233 probes, 
and expression profiles clustered in a data-driven and literature-driven manner.  
3,343,497 genetic variants were used to predict treatment response alone and combined in 
polygenic risk scores. 
Genotype and expression data were combined in expression quantitative trait loci (eQTL) 
analyses.  
Results 
Expression levels were not associated with either treatment phenotype in any analysis.  
1,492 eQTLs were identified with q<0.05, but interactions between genetic variants and 
treatment response did not affect expression levels significantly.  
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 Genetic variants did not significantly predict treatment response alone or in polygenic risk 
scores. 
Conclusions 
We assessed gene expression alone and alongside genetic variants. No associations with 
treatment outcome were identified. Future studies require larger sample sizes to discover 
associations.   
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 Introduction 
 Anxiety disorders are the most common group of mental illnesses, with lifetime 
prevalence estimates ranging between 10-30% (Kessler et al 2007; Michael et al 2007). They are 
an economic burden on society and the sixth largest cause of disability globally (Baxter et al 
2014; Fineberg et al 2013). Suffering from an anxiety disorder is distressing, with affected 
individuals reporting adverse effects on quality of life comparable to sufferers of major 
depressive disorder, and in excess of the population norm (Mendlowicz and Stein 2000).  
Treatment of anxiety disorders uses a variety of pharmacological and psychological 
modalities (National Collaborating Centre for Mental 2011). Exposure-based cognitive 
behavioural therapy (eCBT) is a common treatment, and shows large effect sizes across the 
anxiety disorders, comparable to or better than those obtained by anxiolytic medication (Barlow 
et al 2013; Cuijpers et al 2013; Margraf and Zlomuzica 2015; Norton and Price 2007; Stewart 
and Chambless 2009). During eCBT, participants confront the object of their anxiety (whether 
literally, referred to as in vivo, or through imagination or virtual reality, referred to as in sensu), 
within a carefully managed and supportive environment. They identify the cognitive and 
behavioural processes underlying their anxious response, and develop strategies to mitigate 
against these negative schema and to cope with their anxiety (Otto et al 2004). Rates of response 
(in terms of a reduction in symptom severity) and of remission (no longer meeting diagnostic 
criteria) vary between specific disorders and studies, but are invariably less than 100% 
(Ballenger 1999; Hofmann et al 2012; Loerinc et al 2015; Olatunji et al 2010).  
Numerous influences have been proposed to lead to poorer treatment outcome, including 
high initial severity, Axis I and Axis II comorbidity, illness duration, low expectancy of 
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 treatment success, poor treatment compliance and therapeutic alliance, and general interpersonal 
difficulties (Newman et al 2013). However, studies disagree on the importance and validity of 
such predictors (Olatunji et al 2013; Schneider et al 2015; Taylor et al 2012). The success of any 
specific treatment for a given participant is difficult to predict. This is relevant given the high 
costs (both economic and emotional) of pursuing unsuccessful treatment (Otto et al 2000). It is 
of clear interest to develop reliable predictors of treatment response. 
 Genetic variants represent a potential source of predictors. The study of such variants 
(termed therapygenetics) has largely been confined to candidate gene studies (Eley et al 2012; 
Lester and Eley 2013). However, these findings have proven difficult to replicate, and the 
direction of effect found has been inconsistent between studies (Lester et al 2016). Recently, we 
published a GWAS of therapy response in a cohort of children with anxiety disorders (Coleman 
et al 2016). Although underpowered to identify the small-effect variants typical of behavioural 
phenotypes, sufficient power was available to test some effect sizes reported in the 
therapygenetic literature. No variants were found at conventional genome-wide significance, and 
candidate variants were not replicated. Therefore, the effects of individual genetic variants on 
response to CBT are likely to be small, and that the predictive effects of such variants are likely 
to be negligible when used alone. 
 Studying the differential expression of gene transcripts may be more useful for predicting 
treatment response. Multiple factors affect gene expression, potentially including genetic variants 
and environmental influences. Gene expression represents a biologically relevant means of 
combining genetic and environmental variation to predict response to CBT for anxiety disorders. 
Two studies have found an association between increased expression of FKBP5 and response to 
CBT for PTSD (Levy-Gigi et al 2013; Yehuda et al 2013). A recent analysis of change across 
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 treatment including a subset of the cohort presented within this paper showed no association 
between treatment response and individual gene expression, nor when expression was clustered 
according to similarities in expression in the data (Roberts et al Under Review). 
 This investigation combines genetic and gene-expression approaches to predict response 
to eCBT. It assesses the interaction of differential gene expression at baseline (both of individual 
transcripts, and using data-driven and literature driven clustering methods) and genetic variation 
to assess the outcome of eCBT for panic disorder and specific phobias. 
Method 
Participants and therapeutic procedure 
244 participants diagnosed with panic disorder or a specific phobia completed one of four 
exposure-based CBT treatment programs at the Mental Health Research and Treatment Center, 
Ruhr-Universität Bochum, Germany as part of standard care. In all programs, diagnoses were 
made according to DSM-IV criteria using the Diagnostisches Interview bei psychischen 
Störungen (DIPS) and Mini-DIPS, structured interviews with well-established reliability, validity 
and patient acceptance (Bruchmuller et al 2011; In-Albon et al 2008; Margraf 1994; Schneider 
and Margraf 2011; Suppiger et al 2009; Suppiger et al 2008). All treatment programs featured 
core elements of exposure therapy, including psychoeducation, applied relaxation and exposure 
(in vivo or in sensu). Specifics of each treatment program are described below. All treatments 
were regularly supervised by experienced senior clinicians using audio-visual recordings in order 
to ensure treatment protocol integrity. 
Individuals diagnosed with a specific phobia of receiving dental treatment, not secondary to a 
separate diagnosis (such as PTSD or injection phobia), were treated in a dental anxiety-specific 
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 program (DA; (Wannemuller 2015)). Treatment was given in five weekly sessions comprising an 
initial diagnostic and psychoeducation session, a session developing relaxation techniques, and 
three in sensu exposure sessions related to dental treatment. Participants were not excluded on 
the basis of concurrent treatment with anxiolytic medication. 
Participants with specific phobia (SP) not primarily associated with dental fear were treated in a 
longer-term program covering up to thirty sessions, split into five initial sessions of diagnosis 
and psychoeducation, and twenty-five sessions of in vivo exposure (relevant to their specific 
phobia) with elements of cognitive restructuring. Participants were excluded from the study if 
they were using anxiolytic medication.  
Participants with a primary diagnosis of panic disorder with agoraphobia, or agoraphobia alone, 
were randomized either to exposure-based CBT (PD-CBT; akin to the specific phobia group) or 
to an exposure-alone condition without any element of cognitive restructuring (PD-EXP; Clinical 
Trials: NCT01680327). Participants in both conditions were excluded if they were using 
anxiolytic medication. Bodily sensation was used as the specific exposure stimulus for 
participants suffering from panic disorder. However, as there were no patients with panic 
disorder without agoraphobia in the trial, interoceptive exposure was always combined with in-
vivo exposure. 
Prior to receiving exposure, immediately following completion of the treatment program, and at 
a follow-up assessment approximately six months after treatment completion, all participants 
completed a range of questionnaire measures. In addition, peripheral blood was drawn for DNA 
and RNA extraction.   
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 Phenotype definition 
Treatment response was defined as percentage improvement in the clinician-rated severity scale 
of the Clinical Global Impression rating (CGI-S), and was examined pre-treatment to post-
treatment, and pre-treatment to follow-up. The CGI-S ranges from 1-7, with a score of 1 
representing no symptoms of concern and a score of 7 representing extremely severe illness 
requiring hospitalization (Guy 1976). The scale was chosen as it was used in all treatment 
groups, and was expected to capture severity in a disorder-independent fashion. 
The CGI-S was rescaled to range from 0-6 to allow outcome to be defined as percentage 
decrease in severity across time (as this has previously been used successfully in 
pharmacogenetic GWAS) with 100% indicating full remission (Uher et al 2010). For both 
phenotypes, correlations were calculated between percentage improvement and a variety of 
covariates: age, gender, severity at baseline, presence of comorbid mental disorders, number of 
treatment sessions attended, treatment period (days between pre-treatment and post-treatment 
assessment), follow-up period (days between post-treatment assessment and follow-up 
assessment), use of psychoactive medication at pre-treatment, use of any other medication pre-
treatment, body mass index and whether the participant smoked. Although the use of concurrent 
anxiolytic medication was an exclusion criterion for the SP, PD-CBT and PD-EXP groups, some 
participants were using other medications which may have a psychotropic effect, so this 
covariate was not restricted to the DA group (Table 1). 
Of these covariates, severity at baseline, presence of comorbid mental disorders, use of 
psychoactive medication and follow-up period were correlated with at least one phenotype in the 
whole cohort (Table 2). In secondary examinations within each treatment group, treatment period 
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 was associated with at least one phenotype in both the PD-CBT (p=0.014) and SP groups 
(p=0.012). Body mass index (BMI) was weakly associated (p=0.0424) with response at post-
treatment in the PD-CBT group; however, as this effect was not seen in any other group nor in 
the whole cohort, BMI was not included as a covariate.  
The phenotypes for analysis were defined as the residuals from two linear mixed regressions 
investigating change in severity between pre-treatment and post-treatment, and pre-treatment and 
follow-up. Percentage decrease in severity was regressed on fixed effects of baseline severity, 
presence of comorbid mental disorders, use of psychoactive medication, treatment period (and 
follow-up period in the analysis pre-treatment to follow-up), and a higher-order random effect of 
treatment group (to account for differences between treatment groups).  
Genotyping 
DNA was extracted from peripheral blood drawn pre-treatment using Qiagen FlexiGene DNA 
kits, following the protocol provided by the manufacturer (Qiagen Ltd). DNA concentration was 
quantified using spectrophotometry (Nanodrop 1000, Nanodrop, Wilmington, DE), and samples 
diluted to 40µl at a concentration of 75ng/µl for genotyping. Genotyping was performed using 
the Illumina PsychChip microarray (Illumina, San Diego, CA), a modified version of the 
Illumina HumanCoreExome microarray with additional content of interest in psychiatric 
genomics. All laboratory procedures were performed at the Institute of Psychiatry, Psychology 
and Neuroscience, KCL.   JU
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 Genotype quality control 
Quality control was performed following a previously published protocol (Coleman et al 2015). 
In brief, genotype data was called using Illumina GenomeStudio software, with manual recalling 
where appropriate. Rare variants were recalled using ZCall (Goldstein et al 2012). Variants were 
removed from the analysis if they were rare (minor allele frequency<0.05), present in<99% of 
individuals, or deviated substantially from Hardy-Weinberg equilibrium (Hardy-Weinberg test 
p<1x10-5). Individuals were excluded if they had genotype calls for<99% of variants, where 
reported gender differed from that indicated by the genotypes, or if genome-wide estimates of 
heterozygosity >3 standard deviations from the sample mean. Additional exclusions were made 
if the individual showed cryptic relatedness to other individuals in the study (IBD>0.1875) or 
had an average proportion of variants shared IBD with the cohort as a whole >6 standard 
deviations above the cohort mean.  
Following quality control, variants were imputed to the Phase 3 release from the 1000 Genomes 
Project, using IMPUTE2 with concurrent phasing (1000GenomesConsortium 2012; Howie et al 
2012). X chromosome variants were imputed using the March 2012 Phase 1 release 
(1000GenomesConsortium 2012; Howie et al 2012). Imputed variants were imported into 
PLINK2 for analysis, and filtered to remove uncertain variants (posterior-probability<0.8) and 
poorly-imputed variants (info<0.8) (Chang et al 2015). Following hard-calling, variants present 
in<98% of the cohort were dropped from analysis. 
Gene expression 
Whole blood samples were drawn at pre-treatment using PAXgene blood RNA tubes. Blood 
RNA was isolated and purified using the PAXgene Blood miRNA Kit according to the 
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 manufacturer’s protocol using the Qiagen Qiacube (Qiagen). RNA quality was measured using 
spectrophotometry (Nanodrop 1000, Nanodrop, Wilmington, DE) and integrity using an Agilent 
2100 Bioanalyzer (Agilent, Santa Clara, CA). Genome-wide expression levels were measured 
from 750ng total RNA using the Illumina HumanHT-12v4 Expression Beadchip (Illumina, San 
Diego, CA). 
Gene expression quality control 
Raw expression data were processed following internal pipelines (available at 
https://github.com/snewhouse/BRC_MH_Bioinformatics). Samples with detection rates 
dissimilar from the rest of the cohort were identified and removed in GenomeStudio (Illumina, 
San Diego, CA). Raw data was imported into R for quality control primarily using the lumi 
package (Du et al 2008; Team 2012). Expression data was background corrected using Module-
based Background Correction for Beadarray (Ding et al 2008). Probes with an expression level 
>2 standard deviations above the background mean were defined as detected. XIST gene 
expression (specific to females) and Y chromosome gene expression (specific to males) was 
compared to reported gender and gender inferred from genotyping, and discordant samples 
removed. Expression data was log2 transformed and normalized using robust splines 
normalization from the lumi package (Du et al 2008; Schmid et al 2010). Sample co-expression 
relationships were assessed, and samples with connectivity <2 standard deviations from the 
cohort mean were excluded (Oldham et al 2012). Associations between covariates and the first 
principal component of the expression data were assessed using stepwise linear regression 
bootstrapped 100 times, with randomized order of covariates in the regression. Covariates 
included batch variables (expression microarray, sample position on microarray, date of RNA 
extraction, date of expression measurement, machine used in RNA isolation, RNA integrity 
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 (RIN) value, RNA yield, amplified concentration of RNA, whether the sample required 
additional treatment to remove DNA and whether the blood sample was the first or second 
drawn) and demographic covariates (body mass index and smoking). The effect of associated 
covariates was regressed out of the expression data, using sva's ComBat package in the case of 
categorical variables (extraction date) and linear regression (with RcppArmadillo) in the case of 
continuous variables (RIN value, RNA yield, amplified concentration of RNA) (Eddelbuettel and 
Sanderson 2014; Johnson et al 2007). Probes detected in <80% of the sample were removed. As 
expression data was generated from whole blood without assessment of cellular composition, 
deconvolution methods implemented in CellMix were used to assess the origin of RNA 
transcripts before and after differentially expressed probes were selected (Gaujoux and Seoighe 
2013). Correlations between the estimated final proportions of leukocytes (neutrophils, 
lymphocytes and monocytes) and the two CBT response phenotypes were calculated. Additional 
exclusion of probes was performed to allow combined analysis with genotyped variants. 
Specifically, probes were excluded if they were not annotated in the ENSEMBL hg19 build, if 
they contained any genetic variant genotyped in the cohort, or if they did not map to a unique site 
on the genome. Probes were identified using nucleotide universal identifiers (nuIDs), which are 
unique to the DNA sequence of the probe (Du et al 2007). 
Statistical analysis 
Following quality control, the association of genome-wide genotyping data with both response 
phenotypes was assessed in genome-wide association studies (GWAS). The participants in the 
study were of Central or Eastern European ancestry. Genomic estimation of ancestry was 
established using principal components analysis performed in EIGENSOFT (Price et al 2006). 
No principal component was correlated with either of the phenotypes at a level greater than 
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 chance. To account for finer-scale population stratification, analyses were run using a linear 
mixed model incorporating a random effect of gross genetic similarity between individuals (the 
mlma-loco option in GCTA (Yang et al 2011)). Results were clumped in PLINK2, pruning all 
variants in linkage disequilibrium (r2>0.25, +/- 250 kb) of a variant with a lower p-value. 
Genotype information was used as a target dataset in polygenic risk scoring. Specifically, the 
results of a previous GWAS of CBT response in children were used to predict both phenotypes 
in the whole cohort using PRSice, which performs high-resolution polygenic risk scoring to 
identify the most predictive risk score (Coleman et al 2016; Euesden et al 2015). Further GWAS 
were performed on the cohort minus individuals treated for dental anxiety, and the results from 
these subset GWAS were used to predict response to treatment in the dental anxiety subgroup.  
Probe-level expression data was imported into R, and analysed using Weighted Gene Correlation 
Network Analysis (WGCNA (Langfelder and Horvath 2008)). Data-driven clustering of co-
expressed probes was performed using an automatically-constructed signed network from the 
blockwiseModules function in WGCNA (details on this procedure are provided in the 
Supplementary Methods (Langfelder and Horvath 2008)). Correlations between individual 
probes and both response phenotypes, and between WGCNA module eigengenes and response 
phenotypes, were calculated. Local false discovery rates were calculated to account for multiple 
testing using the qvalue package in R (Dabney et al 2004).  
Probe-level correlations were mapped to HUGO gene names, ranked according to significance 
and used in Gene Ontology enrichment analysis in GOrilla (Eden et al 2009). Where multiple 
probes mapped to the same gene, the highest-ranked was retained. Details of the enrichment 
analysis performed by GOrilla are provided in the Supplementary Methods. Significance was set 
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 as the Bonferroni correction for the 8746 GO terms tested (p=5.72x10-6), with results reported 
below p=5x10-4. Results were pruned for redundancy in REViGO, with results with >50% 
dispensability dropped (Supek et al 2011). 
Probe-level expression data was combined using a machine-learning approach in WEKA, to 
assess the viability of prediction from expression probe data alone (Hall et al 2009). Classical 
machine learning algorithms were used to predict outcome using the full dataset (3,233 
expression probes, 166 participants for baseline to post-treatment analysis, 110 participants for 
baseline to follow-up analysis). Five approaches were used: mean prediction with ZeroR; inverse 
distance weighting with a nearest neighbours algorithm (kNN), with and without subset 
evaluation; linear kernel-based regression with Regression SVM (SMOReg) and a 500-tree 
Random Forest algorithm. Multiple algorithms were chosen as they optimise different aspects of 
the learning process. All analyses were performed using 10-fold-cross validation (splitting the 
cohort into 80% training and 20% test subsamples), repeated 5 times.  
Probe-level expression data and genotype data were imported into R for eQTL analyses using the 
MatrixEQTL package (Shabalin 2012). All transcripts captured by the assessed probes were 
mapped to the hg19 build of the human genome. Analyses were performed using a two-stage 
design. Cis-eQTLs were calculated independent of the phenotype, using the modelLINEAR 
option and genotypes from a window ±100kb of the transcript. Linkage-independent results were 
obtained by clumping using PLINK2 (250kb window, r2< 0.25), and by performing conditional 
eQTL analyses (Chang et al 2015). Both techniques identified the same sentinel SNPs (data not 
shown). Clumped results were retained for the second, phenotype-dependent, stage. SNP-by-
treatment response interactions predicting expression change were assessed for both phenotypes, 
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 using the modelLINEAR_CROSS option in MatrixEQTL, to investigate whether the effect of 
eQTLs in the data differed in relation to treatment response. 
Power analyses for the expression analyses were performed using the pwr package in R. 
Ethics 
Ethics approval for this study was received from the Ethics Committee at the Faculty of 
Psychology, Ruhr-Universität Bochum, from the London-Bentham NRES Committee and from 
the King’s College London Psychiatry, Nursing and Midwifery Research Ethics Sub-Committee. 
All participants provided informed consent. The study was conducted in accordance with the 
principles outlined in the Declaration of Helsinki.  
Results 
Phenotype data was available on 187 participants (185 at post-treatment; 122 at follow-up). 
Following quality control, genotype data was available on 3,343,497 variants (267,037 
genotyped) for 181 participants for the post-treatment analysis (122 were available for the 
analysis at follow-up). Data from 3,233 expression probes were available on 166 (110) 
participants. Both data types were available on 162 (110) participants.  
Demographics and clinical covariates 
Demographic data on the cohort are displayed in Table 1. Individuals in the SP group had lower 
baseline severity than all other groups. Groups also differed by mental disorder comorbidity, 
with individuals in the DA group exhibiting more comorbidity than other groups, and 
significantly more than the SP group (details of mental comorbidities are provided in 
Supplementary Table 1). As expected, there was a higher rate of psychoactive medication use in 
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 the DA group compared to all others. Treatment duration also differed significantly across the 
groups, with shorter treatment in the DA group than in all others. Follow-up duration was 
significantly longer in the DA group. All covariates showing inter-group differences were 
included as covariates when defining the treatment response phenotypes (as was a random effect 
of treatment group; Table 2). 
[Approximate position of Tables 1 and 2] 
Changes in CGI from pre-treatment to post treatment and to follow-up are described in Table 3. 
All treatments were generally effective, with most participants improving on the CGI-S between 
pre-treatment and post-treatment, and between pre-treatment and follow-up. However, there was 
considerable variance in the percentage change shown between individuals. Demographic 
differences between response groups following treatment are described for the whole cohort in 
Supplementary Table 2. Significantly lower baseline severity and higher comorbidity was 
observed in those deteriorating compared to those improving. No other significant differences 
were observed.  
[Approximate position of Table 3] 
GWAS and polygenic risk score analysis  
Results from both GWAS are shown in Supplementary Table 3, and Supplementary Figures 1 
and 2. No variants passed the threshold for genome-wide significance (p= 5x10-8), but three 
independent loci in the analysis to post-treatment and four loci in the analysis to follow-up 
reached a suggestive level of significance (p<5x10-6). Quantile-quantile plots indicated no 
substantial genomic inflation in either analysis.  
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 Polygenic risk score analysis from an independent GWAS of response to CBT in children failed 
to predict response in the whole cohort with p<0.001 (Supplementary Table 4a, threshold 
adjusted for multiple testing (Euesden et al 2015)). Prediction between the DA treatment group 
and all other treatment groups explained more variance in outcome than the analysis using the 
independent GWAS, but predictors were not significant (Supplementary Table 4b). Further 
discussion of the GWAS and PRSice analyses are included in the Supplementary Material. 
Individual expression probes 
No probes were significantly associated with either phenotype after correcting for multiple 
testing (all q> 0.05; Table 4). The probes with the lowest q-values in this analysis showed no 
overlap with those reported in a parallel analysis of this cohort, examining change in expression 
over the course of treatment (Roberts et al Under Review). 
Power analyses indicated the analyses have 80% power to detect associations capturing at least 
14.8% (post-treatment), and 19.6% (follow-up) of variance respectively, where alpha= 1.55x10-5 
(Bonferroni-correction for 3233 tests).  
[Approximate position of Table 4] 
Data-driven network-based analyses 
Clustering by co-expression patterns yielded eight network modules ranging from 750 to 63 
probes and a further "grey" module of 459 probes that did not fall into any cluster. Although 
different clusters showed associations with a variety of sample characteristics, no cluster was 
associated with either treatment response phenotype (all p>0.05; Figure 1).  
[Approximate position of Figure 1] 
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 Literature-driven gene ontology analysis 
HUGO gene names were assigned to 2,652 probes associated with at least one GO term (process, 
function or component). No significant pathways were found after correction for multiple testing 
(all p>5.72x10-6). Following removal of redundant GO terms, five processes and one function 
were associated with p<5x10-4 in the analysis from baseline to post-treatment. From baseline to 
follow-up, eight processes and two functions were associated with p<5x10-4 (Supplementary 
Table 5).  
Classical machine learning analyses 
Classical machine learning methods did not outperform the null model in either analysis. The 
most effective model was random forest classification (root mean square error: 31.3 (post-
treatment), 42.7 (follow-up)) but this did not outperform ZeroR, which predicts the mean 
(RMSE: 30.6 (post-treatment), 42.3 (follow-up).  
Expression quantitative trait loci 
Expression quantitative trait locus (eQTL) analysis identified 42,868 cis-eQTLs with q<0.05, 
independent of phenotype. Following the removal of variants in linkage disequilibrium with 
more strongly associated eQTLs, 1,492 variants were present with q<0.05 (Table 5, 
Supplementary Table 5). Phenotype-dependent analyses of the interaction between these variants 
and treatment response predicting expression levels yielded no associations with q<0.05 (Table 
6). One interaction was identified with q<0.2 (rs10498246 x treatment response baseline to 
follow-up, predicting SP110 (probe nuID: fcV3S0U75If1e3op0U) expression, B=-0.0041, 
p=2.23x10-5, q=  0.103). 
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 [Approximate position of Tables 5 and 6] 
Discussion 
We performed genome-wide analysis of genetic variation and pre-treatment gene expression to 
assess independent and combined effects on response to CBT for anxiety disorders in a cohort of 
adult participants. This is the first analysis to integrate this data in studying psychological 
treatment response, and (together with a companion paper; (Roberts et al Under Review)) is an 
analysis of the largest psychological treatment cohort in which gene expression analyses have 
been performed. Despite this, no variants or expression profiles were associated (at a genome-
wide level of significance) with treatment response across the treatment period or at a six-month 
follow-up.  
The cohort is larger than previous studies of the effect of gene expression on response to CBT in 
anxiety disorder (Levy-Gigi et al 2013; Yehuda et al 2013). However, it is clear that this study is 
underpowered to detect all but the largest effects on response, and that robust prediction requires 
larger cohort sizes. Integrating data from two different approaches (that is, genotyping and gene 
expression) increases power, but requires two sets of quality control, resulting in fewer samples 
with full data available (Ritchie et al 2015). Obtaining a large sample size for a study such as this 
is non-trivial. Prospective recruitment results in a high rate of attrition as participants withdraw 
from treatment or are lost to follow-up. Furthermore, this attrition is likely to be related to poor 
treatment response.  
The aim of this investigation was to study genetic and transcriptomic correlates of response to 
exposure-based therapy, which may act across diagnostic boundaries. We sought to increase 
power by recruiting from treatment studies for two disorders with differing treatment procedures. 
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 Studying anxiety disorders as a heterogeneous group has been effective in genomics (Otowa et al 
2016). However, combining groups increases heterogeneity, partially negating the increased 
power from the enlarged sample size. The disorders studied are conceptually distinct, and 
treatment is tailored to the needs of the participant, differing between and within diagnostic 
groups. Combining across disorder groups incurs disorder-specific differences, such as the lower 
baseline severity of the SP group and higher comorbidity in the DA group herein. These 
differences reflect the varying nature of the disorders and recruitment to treatment – for example, 
the high comorbidity of the DA group is likely to result from secondary consequences of 
avoiding dental treatment, such as a phobia of vomiting or social anxiety about visiting the 
dentist. Although we have sought to control for this heterogeneity statistically, it limits the 
conclusions of this investigation. Furthermore, many social and environmental influences on 
treatment response have been proposed, and the covariates controlled for within this analysis 
cannot correct for all possible confounds. Nevertheless, investigating biological correlates of 
therapy requires a pragmatic approach. Cohorts of individuals receiving psychological therapies, 
particularly those outside of clinical trials, are prone to heterogeneity and attrition. For any 
biological predictor to contribute valuably to therapeutic decision-making, it must be robust to 
these limitations.  
Although no genome-wide gene expression studies have investigated response to CBT, single-
gene studies have suggested a role for differential FKBP5 expression in response to CBT for 
PTSD (Levy-Gigi et al 2013; Yehuda et al 2013). One probe in this study, 
ZdI45Se3VG7s869FKo, captures expression of FKBP5, but was not associated with either 
outcome (baseline to post-treatment: p=0.0533, q=0.999; baseline to follow-up: p=0.607, 
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 q=0.997). However, the low power of the analysis (and differences between this cohort and those 
examined previously), limit strong conclusion..  
Gene expression differs between different tissues and organs; expression observed in peripheral 
blood may not reflect that in the brain. Previous studies suggest moderate correlation between 
gene expression in different tissues, varying by individual genes (Sullivan et al 2006). The 
emergence of reference panels such as the GTEx Portal has made in silico assessment of blood-
brain expression correlations at the individual gene level viable (Consortium 2015). As such, 
peripheral blood gene expression can provide relevant insights into gene expression in the brain, 
and this will improve as further brain expression samples are added to the reference. From a 
pragmatic standpoint, gene expression markers of treatment response will only be useful if they 
can be obtained from peripheral tissues – while the effect of gene expression in brain tissues is of 
biological interest, it cannot be of practical utility in this case.  
Assessing the severity of anxiety disorders can be performed using different rating scales, with 
varying characteristics. No consensus regarding the best means of measuring response to CBT 
exists (Loerinc et al 2015). In this study, the CGI-S was used as a measure of clinical concern 
across treatment groups, allowing a single measure to be used to assess general functioning. 
However, this measure bears a number of limitations. It is a subjective measure of clinical 
judgement that may fail to capture the participant's anxiety as appropriately as a self-report 
measure. Treatment response is likely to involve multiple components, including reduction in 
fear and increase in functioning, that a single measure may not capture. One potential solution is 
to combine a number of scales using different assessors and assessing different aspects of 
treatment response. However, this increases the complexity of the analysis and the potential for 
spurious results. In addition, it would be difficult to interpret in a useful manner.  
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 Anxiety disorders are widespread and disabling, and CBT is a first-line treatment for these 
conditions. CBT involves a considerable investment from the recipient, and a significant 
minority of those receiving it do not respond adequately. Stable pre-treatment predictors of 
outcome are required. To date, genetic variants and gene expression levels have not provided 
these predictors, individually or in combination. However, this does not argue against the 
continued study of the biology underlying CBT response. The pattern of findings to date is 
consistent with the highly polygenic model that has been proposed to influence behavioural traits 
(Chabris et al 2015). Although individual genetic variants seem extremely unlikely to be 
valuable predictors, prediction might be achieved through the combined effect of many genetic 
variants, at multiple levels of analysis. 
Response to CBT is likely to be influenced by genes and by the environment, and continued 
research to define reliable environmental and clinical predictors of response is vital –genetics can 
only be clinically useful in the context of known environmental and clinical risk factors (Hudson 
et al 2015). Studies of genetic variation, gene expression and epigenetics should either adopt a 
hypothesis-neutral approach (exploring variation genome-wide), or be informed by robust 
associations in related traits (rather than assumed biological relevance). The effects of individual 
transcript differences are likely to be small. For these insights to be discovered, cohorts of 
thousands of individuals must be treated in as homogenous a manner as possible from 
recruitment to the analysis of the resulting data. This is not straightforward (especially given the 
heterogeneity inherent to CBT) but the example of the many international consortia driving 
advances in complex trait genetics demonstrates such investigations can yield valuable insights. 
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 Tables 
Table 1 
Variable WC DA SP PD-CBT 
PD-
EXP Test 
St
at p 
N 187 95 38 25 29 
- - - 
Age in years  
(Mean [SD]) 
39.2 
[11.4] 
40.5 
[10.4] 
37.8 
[13.2] 
38.4 
[11.9] 
37.4 
[11.9] 
AN
OV
A 
0.8
31 
0.47
8 
Gender  
(N male [%]) 
67 
[35.8] 
35 
[36.8] 
9 
[23.7] 
13 
[52.0] 
10 
[34.5] 
Chi 
squa
re 
5.3
5 
0.14
8 
Baseline CGI severity  
(Mean [SD]) 
4.70 
[1.13] 
4.83 
[1.27] 
4.16 
[0.973
] 
4.80 
[0.707
] 
4.86 
[0.915
] 
AN
OV
A 
3.8
0 
0.01
12 * 
Treatment duration in days 
(Mean [SD]) 
200 
[184] 
47.6 
[32.8] 
340 
[152] 
351 
[118] 
383 
[137] 
AN
OV
A 
15
1 
3.15
x10-
49 † 
Follow-up duration in days 
(Mean [SD]) 
215 
[62.7] 
249 
[72] 
191 
[41.4] 
190 
[35.4] 
191 
[44.7] 
AN
OV
A 
11.
4 
4.32
x10-
7 ‡ 
Psychoactive medication at 
baseline (N taking [%]) 
20 
[10.7] 
18 
[18.9] 
1 
[2.63] 
1 
[4.00] 
0 
[0.00] 
Fisher's 
exact test 
0.00
247 
§ 
Mental disorder 
comorbidities  
(N [%]) 
72 
[38.5] 
46 
[48.4] 
8 
[21.1] 
9 
[36.0] 
9 
[31.0] 
Chi 
squa
re 
9.5
8 
0.02
25 ¶ 
Table 1: Demographic and treatment information on participants with genotype and/or 
expression data. 
Post-hoc t-tests (variances assumed unequal; Bonferroni corrected significance threshold = 
0.00834; significant results in bold): 
* = SP lower: vs DA: t=-3.29, p=0.00143; vs PD-CBT: t=-3.03, p=0.00361; vs PD-EXP: t=-
3.04, p=0.00350  
† = DA shorter: vs SP: t=-11.7, p=2.79x10-14; vs PD-CBT: t=-12.8, p=1.93x10-12; vs PD-EXP: 
t=-13.0, p=1.19x10-13 
‡ = DA longer: vs SP: t=4.96, p=3.19x10-6; vs PD-CBT: t=4.86, p=6.93x10-6; vs PD-EXP: 
t=4.48, p=2.74x10-5 
§ = Higher rate in DA: vs SP: t=3.38, p=9.47x10-4; vs PD-CBT: t=2.63, p=0.0103; vs PD-EXP: 
t=4.69, p=9.33x10-6 
¶ =Higher rate in DA: vs SP: t=3.24, p=0.00174; vs PD-CBT: t=1.12, p=0.269; vs PD-EXP: 
t=1.71, p=0.0930 
Groups: WC = Whole cohort, DA = Dental anxiety, SP = specific phobia, PD-CBT = panic 
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 disorder CBT,  
PD-EXP = panic disorder exposure 
Table 2 
Correlations between clinical covariates and treatment response phenotypes for the whole 
cohort (N= 187) 
 Post-treatment Follow-up 
Variable r p r p 
Age (years) -0.0536 0.469 0.0212 0.816 
Gender 0.045 0.543 0.0497 0.585 
Baseline CGI severity 0.112 0.128 0.303 7x10-4 
Treatment sessions 0.129 0.0818 0.106 0.255 
Treatment duration (days) 0.117 0.111 0.0189 0.835 
Follow-up duration 
(days) 
-0.178 0.0409 -0.0411 0.6614 
Psychoactive medication 
(use) 
-0.205 0.00521 -0.203 0.0243 
Other medication (use) -0.0483 0.514 -0.117 0.200 
Mental comorbidity 
(yes/no) 
-0.210 0.00407 -0.188 0.0379 
Body mass index 0.0572 0.440 0.0008 0.993 
Smoker (yes/no) -0.0317 0.687 0.0146 0.880 
 
Table 2: Correlations between clinical covariates and treatment response phenotypes for the 
whole cohort (N= 187). Correlations with nominal significance (p<  0.05) are highlighted in bold. 
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 Table 3 
Response post 
treatment 
Whole 
cohort DA SP 
PD-
CBT 
PD-
EXP Test 
St
at p 
N 185 95 37 24 29 - - - 
 % change in CGI 
(Mean [SD]) 
67.4 
[34.6] 
62.0 
[32.1] 
77 
[39.5] 
67.1 
[37.1] 
72.9 
[31.8] 
ANO
VA 
2.0
1 
0.1
15 
Improved (N [%]) 165 [89.2] 84 [88.4] 
33 
[89.2] 
21 
[87.5] 
27 
[93.1] 
Fisher's 
exact test 
0.6
13 No change (N [%]) 16 [8.65] 10 [10.5] 2 [5.41] 2 [8.33] 2 [6.90] 
Deteriorated (N [%}) 4 [2.16] 1 [1.05] 2 [5.41] 1 [4.17] 0 [0.00] 
Response at follow-
up 
Whole 
cohort DA SP 
PD-
CBT 
PD-
EXP Test 
St
at P 
N 122 54 32 17 19 - -  
% change in CGI 
(Mean [SD]) 
59.7 
[46.2] 
52.3 
[54.5] 
71.4 
[37.9] 
71.5 
[30.7] 
49.8 
[41.2] 
ANO
VA 
1.9
0 
0.1
34 
Improved (N [%]) 101 [82.8] 42 [77.8] 
28 
[87.5] 
16 
[94.1] 
15 
[78.9] Fisher's 
exact test 
0.6
41 No change (N [%]) 11 [9.02] 5 [9.26] 3 [9.38] 1 [5.88] 2 [10.5] 
Deteriorated (N [%]) 10 [8.20] 7 [13.0] 1 [3.13] 0 [0.00] 2 [10.5] 
 
Table 3: Treatment response as percentage change in CGI-S, and grouped by improvement 
(percentage change positive), no change, and deterioration (percentage change negative), in the 
whole cohort and each treatment. Groups did not differ on treatment response by either measure. 
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 Table 4 
Associations between expression probes and treatment outcome 
Baseline – post-treatment 
Probe nuID Gene WGCNA module Pearson's r p q 
TkiT0uUa.K4LZ5M7h4 FDFT1 blue 0.282 2.34x10-4 0.756 
0Z7unqF.KAuA5K4ggU FDFT1 grey 0.241 0.00175 1 
Eqx.SxEEVcI.VLrWJI IL18RAP grey 0.237 0.00211 1 
Te4VV0giY1VcQvr17E RNASE6 grey -0.216 0.00515 1 
QuynqD354KD6IAXvnk YIPF4 grey -0.214 0.00550 1 
Baseline – follow-up 
Probe nuID Gene WGCNA module Pearson's r p q 
TXm4UjVovoAQ4ApVQo MYC grey -0.346 2.17x10-4 0.702 
Krrborr9LqDhB.rPoo HNRNPA1P33 brown -0.294 0.00180 1 
Ew_iK7UunWqIb0nFeE AIF1 grey 0.265 0.00518 1 
6dFQSN.UitTroIYwV4 MAL grey -0.240 0.0115 1 
T0upGOh1A5dC87MXtU PPP6C turquoise 0.235 0.0136 1 
 
Table 4: Largest correlations between individual expression probes and the treatment response 
phenotypes. WGCNA modules refer to the data-driven clusters to which each probe belongs. 
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 Table 5 
Linkage-dependent and independent blood eQTLs  
FDR q threshold # variants # linkage-independent variants 
0.01 26566 788 
0.05 42868 1492 
0.1 54795 2159 
0.5 61799 2503 
 
Table 5: Raw and clumped results from the expression QTL analysis, by false-discovery rate 
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 Table 6 
eQTL x treatment response predicting gene expression 
Baseline – post-treatment 
SNP Probe nuID Gene Beta p q 
rs11260538 94gYDdn0tHeWCmeGk0 SDF4 0.00394 7.86x10-4 1 
rs3129996 llGfH57t5ug93Xe1XU KIAA1949 -0.00431 0.00126 1 
rs16965033 onsnvop.hKDoejReHU HERPUD1 -0.00528 0.00155 1 
rs3743888 9Sft35eUe7g2mGiR5E AXIN1 0.00270 0.00163 1 
rs11850781 NoXN6F3SR7AMv_v_6Q NIN -0.00577 0.00164 1 
Baseline – follow-up 
SNP Probe nuID Gene Beta p q 
rs10498246 fcV3S0U75If1e3op0U SP110 -0.00414 2.23x10-5 0.103 
rs6701295 cXl3ddwDJC3qA16ri4 SMG5 0.00249 2.26 x10-4 0.523 
rs1737046 Tt5huq2hqZcdZqzRSc HCG4 -0.00318 3.99 x10-4 0.616 
rs4602357 6oIooHit00T3Imfo5U CEP63 0.00251 5.94 x10-4 0.688 
rs12343854 fpnvXlHteCO4OrrGP0 SEMA4D 0.00231 9.24 x10-4 0.784 
 
Table 6: Top 5 results from eQTL-outcome interactions predicting expression level. 
 No interactions are significant at q<0.05. 
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 Figure Legends 
Figure 1: Correlations between expression profiles of module eigengenes from WGCNA and 
treatment phenotypes (and covariates). Positive correlations are shown in red, negative 
correlations in blue, with colour intensity indicating strength of correlation. No module 
expression profile is associated with a treatment response phenotype (all p> 0.05).  
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